GSK India Reports Strong Q2 FY27 With PAT Up 31% YoY
GlaxoSmithKline Pharmaceuticals Ltd 路 Press Release 路 04 Nov 2026, 12:32 am
GSK India Reports Strong Q2 FY27 With PAT Up 31% YoY GlaxoSmithKline Pharmaceuticals reported revenue of INR 1,180 crore for Q2 FY27 ended 30th Sep'26, up 21% YoY, supported by General Medicines, Vaccines, and Specialty portfolios alongside a favorable base effect. EBITDA rose 20% YoY, while PAT increased 31% YoY to INR 335 crore. Core brands Augmentin, Calpol, Ceftum, and T-bact gained market share, while Shingrix drove adult vaccine growth. The company announced its entry into haemato-oncology with the planned launch of BLENREP for relapsed or refractory multiple myeloma, building on its existing oncology footprint.
Original exchange filing (PDF)
More announcements from GlaxoSmithKline Pharmaceuticals Ltd
- As per attachment 路 08 Nov 2026
- As per attachment 路 05 Nov 2026
- As per attachment 路 05 Nov 2026
- Analyst meet Presentation 路 04 Nov 2026
- As per attachment 路 04 Nov 2026
- As per attachment 路 04 Nov 2026
- outcome of Meeting 路 04 Nov 2026
- GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 04 Nov 2026
